Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Phase 2b Comparability Trial in Adults 18 to 49 Years of Age to Assess Immunogenicity, Safety, and Reactogenicity of the MVA-BN Vaccine Manufactured in Different Production Cells

NCT07199569 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT07199569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07199569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Phase 2b Comparability Trial in Adults 18 to 49 Years of Age to Assess Immunogenicity, Safety, and Reactogenicity of the MVA-BN Vaccine Manufactured in Different Production Cells
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 27, 2025
Completion date
November 30, 2026
Enrollment
970 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

monkeypox (mpox)